

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
高口浩一	C型肝炎治療 Q&A 肝臓専門医の役割は?	伊藤義人 中島淳	最新C型肝炎診断と治療 経口薬治療マニュアル	東京都 療社	東京都	2016	80-81
相崎英樹、和気健二郎、脇田隆字	ここまでわかったC型肝炎ウイルスの感染・複製機構		Mebio	メジカル ビュー社	東京	2017	4-13
相崎英樹、脇田隆字	肝炎ウイルス検査のすすめ		くらしの豆知識	国民生活センター	東京	2016	200-201
相崎英樹、和気健二郎、脇田隆字	ここまでわかったC型肝炎ウイルスの感染・複製機構		Mebio	メジカル ビュー社	東京	2016	4-13
渡士幸一、相崎英樹	B型肝炎ウイルス研究のトピックス、特集:B型肝炎—ワクチン定期接種化にあたって		小児科	金原出版	東京	2016	1107-1111
島上哲朗、金子周一	C型慢性肝疾患の薬剤治療	桑山肇	消化器の臨床	ヴァンメ ディカル	東京都	2016	412-8
飯島尋子	肝細胞癌スクリーニング法。	兵庫医科大学 学内科学肝胆膵科主任 教授 西口修平 編	肝硬変のマネジメント 改訂3版	医薬ジャーナル社		2016	43-48
坂本穰	C型肝炎治療の変遷と現状	伊藤義人、 中島淳監修	最新C型肝炎診断と治療 経口薬治療マニュアル	東京都 療社	東京	2016	2-5
坂本穰、榎本信幸	耐性変異への対策	田中篤編	C型肝炎治療のためのDAAの使い方	文光堂	東京	2016	92-100

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
打田[小林]佐和子, 榎本大, 藤井英樹, 飯田[上野]綾子, 元山宏行, 小塚立蔵, 萩原淳司, 川村悦史, 森川浩安, 村上善基, 田守昭博, 河田則文	当院における肝炎ウイルス検査の実施状況と陽性者に対する受診勧奨システム構築による院内連携の変化について	肝臓	57	7-16	2016
Fujii H, Yamaguchi S, Kurai O, Miyano M, Ueda W, Oba H, Aoki T, Enomoto M, Kawada N, Okawa K	Putting "sticky notes" on the electronic medical record to promote intra-hospital referral of hepatitis B and C virus-positive patients to hepatology specialists: a exploratory study	BMC Infect Dis	16	410	2016
下村泰之、池田房雄、ほか	肝炎ウイルススクリーニング検査陽性患者に対する検査報告システムの構築による肝臓専門医受診率向上への取り組み	肝臓	56号	137-143	2015
眞鍋明広、坂口孝作、佐々木恭、實藤宏美、藪下和久、西田正則、小畠大造、田原麻衣、重西邦浩	肝臓内科以外の診療科でのHBs抗原、HCV抗体陽性症例の肝疾患診療状況	広島医学	69	538-542	2016
Honda Y, Yoneda M, Kessoku T, Ogawa Y, Tomono W, Imajo K, Mawatari H, Fujita K, Hyogo H, Ueno T, Chayama K, Saito S, Nakajima A, Hotta K.	Characteristics of non-obese NAFLD: Effect of genetic and environmental factors.	Hepatol Res	Sep;46(10):	1011-1018.	2016
Tsukuda S, Watashi K, Hojima T, Isogawa M, Iwamoto M, O magari K, Suzuki R, Aizaki H, Kojima S, Sugiyama M, Saito A, Tanaka Y, Mizokami M, Sureau C, Wakita T.	A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins.	Hepatology			in press

Kong L, Fujimoto A, Nakamura M, Aoyagi H, Matsuda M, Watanishi K, Suzuki R, Arita M, Yamagoe S, Dohmae N, Suzuki T, Sakamaki Y, Ichinose S, Suzuki T, Wakita T, <u>Aizaki H.</u>	Prolactin regulatory element binding protein is involved in hepatitis C virus replication compartment by interacting with NS4B.	J Virol.	90	3093-111	2016
Nakajima S, Watashi K, Ohashi H, Kamiuchi S, Izaguirre-Carmona J, Tsukuda S, Okada M, Moi ML, Takeuchi T, Suzuki R, <u>Aizaki H.</u> , Kato T, Suzuki T, Hasegawa H, Takasaki T, Sugawara F, Wakita T.	Fungus-Derived Neochitinulin B as a Novel Antagonist of Liver X Receptor, Identified by Chemical Genetics Using a Hepatitis C Virus Cell Culture System.	J Virol.	90	9058-74	2016
Puig-Basagoiti F, Fukuhara T, Tamura T, Ono C, Uemura K, Kawachi Y, Yamamoto S, Mori H, Kurihara T, Okamoto T, <u>Aizaki H.</u> , Matsuura Y.	Human Cathelicidin Compensates for the Role of Apolipoproteins in Hepatitis C Virus Infectious Particle Formation.	J Virol.	90	8464-77	2016
Saga R, Fujimoto A, Watanabe N, Matsuda M, Hasegawa M, Watanishi K, <u>Aizaki H.</u> , Nakamura N, Tajima S, Takasaki T, Konishi E, Kato T, Kohara M, Takeyama H, Wakita T, Suzuki R.	Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus.	Sci Rep.	27	28688	2016
Suzuki R, Saito K, Matsuda M, Sato M, Kanegae Y, Shi G, Watanishi K, <u>Aizaki H.</u> , Chiba J, Saito I, Wakita T, Suzuki T.	Single-domain intrabodies against HCV1. Core inhibit viral propagation and C-terminally induced NF- κ B Activation.	J Gen Virol.	97	887-92	2016
Takegoshi K, Honda M, Okada H, Takabatake R, Matsuzawa-Nagata N, Campbell JS, Nishikawa M, Shimakami T, Shirasaki T, Sakai Y, Yamashita T, Takamura T, Tanaka T, Kaneko S.	Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model.	Oncotarget	in press	in press	2017

Yamane D, Selitsky SR, Shimakami T, Li Y, Zhou M, Honda M, Sethupathy P, Lemmon SM.	Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3' variants	Nucleic Acids Res	in press	in press	2017
Liu F, Shimakami T, Murai K, Shirasaki T, Funaki M, Honda M, Murakami S, Yamamoto S, Tang H, Kaneko S.	Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems	Sci Rep	6	30939	2016
井上貴子、田中靖人	肝疾患診断における新規バイオマーカーの臨床的意義	臨床病理	65	83-91	2017
Inoue T, Hmwe SS, Shimada N, Kato K, Ide T, Torimura T, Kumada T, Toyoda H, Tsubota A, Takagi K, Wakita T and Tanaka Y.	Clinical significance of two real-time PCR assays for chronic hepatitis C patients receiving protease inhibitor-based therapy.	PLoS One	Jan 24;12(1)	e0170667	2017
井上貴子、五藤孝秋、荻原貴之、大橋実、大池知行、可児里美、新海登、脇本幸夫、佐藤茂、田中靖人	HIV スクリーニングにおける抗原抗体同時検出法の臨床的有用性と偽陽性判定をきたす要因	臨床病理	64	1335-1340	2016
井上貴子、田中靖人	特集：B型肝炎遺伝子型が異なるウイルスに対するB型肝炎ワクチンの効果	雑誌「小児科」	57巻9号	1093-1100	2016
井上貴子、田中靖人	トピックス：肝疾患診療の進歩 B型肝炎を巡る最近の話題	臨床病理	64	771-779	2016
井上貴子、田中靖人	特集／臨床検査の最新情報 感染症の検査 ウイルス性肝炎検査参考	月刊「臨床と研究」 平成28年8月号特集企画	第93巻	51-56	2016
Inoue T and Tanaka Y.	Hepatitis B Virus and Its Sexually Transmitted Infection – an Update.	Microbial Cell	3	420-437	2016

Ishigami M, Hayashi K, Honda T, Kuzuya T, Ishizu Y, Ishikawa T, Nakano I, Ura no F, Kumada T, Yoshioka K, Goto H, Hirooka Y.	Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data.	J Gastroenterol Hepatol	in press	doi: 10.1111/jgh.13779	2017
Ishigami M, Hayashi K, Honda T, Kuzuya T, Ishizu Y, Ishikawa T, Nakano I, Ura no F, Kumada T, Yoshioka K, Goto H, Hirooka Y	Real world data of daclatasvir and asunaprevir combination therapy for HCV genotype 1b infection in patients with renal dysfunction.	Clin Gastroenterol Hepatol	in press	doi: 10.1016/j.cgh.2016.12.009	2016
Honda T, Ishigami M, Ishizu Y, Kuzuya T, Hayashi K, Ishikawa T, Murakami Y, Iwadate M, Umeyama H, Toyoda H, Kumada T, Katano Y, Goto H, Hirooka Y.	The Core I97L mutation in conjunction with P79Q is associated with persistent low HBVDNA and HBs antigen clearance in chronic hepatitis B patients.	Clin Microbiol Infect	in press	doi: 10.1016/j.cmi.2016.12.014	2016
Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Tachi Y, Ishikawa T, Katano Y, Yoshioka K, Toyoda H, Kumada T, Goto H, Hirooka Y.	Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.	J Gastroenterol	51	1081-1089	2016
Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaki T, Honda M, Kaneko S, Gatanaga H, Oka S, Kawamura Y, Dohi T, Shuno Y, Yano H, Mizokami M.	Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogs: a new potential target for hepatitis B virus infection.	Gut	In press		2016
坂本 穣	肝細胞がんの診断とサーベイランス	日本放射線技術学会雑誌	72 (1)	97-105	2016
坂本 穣、榎本信幸	抗ウイルス薬	医薬ジャーナル	52、S-1	305-312	2016
坂本 穣、榎本信幸	C型肝炎 SVR 後の肝発癌関連因子	医学のあゆみ	299 (4)	293-298	2016

Kawai-Kitahara F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, Nitta S, Wanabe T, Otani S, Taniguchi M, Goto F, Nagata H, Kaneko S, Tasaka-Fujita M, Nishimura-Sakurai Y, Azuma S, Itsui Y, Nakagawa M, Tanabe M, Takano S, Fukasawa M, <u>Sakamoto M</u> , Maekawa S, Enomoto N, Watanabe M.	Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.	J Gastroenterol.	May;51(5)	473-86	2016
蓮池 悟、永田賢治、下田和哉	B型肝炎ウイルスの再活性化について	宮崎県内科医会誌	89	29-33	2016年
Hirashima N, Iwase H, Shimada M, Ryuge N, Imamura J, Ikeda H, Tanaka Y, <u>Matsumoto N</u> , Okuse C, Itoh F, Yokomaku Y, Watanabe T.	Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.	Clin J Gastroenterol	10(1)	41-46	2017
Ikeda H, Watanabe T, Okuse C, <u>Matsumoto N</u> , Ishii T, Yamada N, Shigefuku R, Hattori N, Matsunaga K, Nakano H, Hiraishi T, Kobayashi M, Yasuda K, Yamamoto H, Yasuda H, Kurosaki M, Izumi N, Yotsuyanagi H, Suzuki M, Itoh F.	An Hepatitis C Virus (HCV)/HIV Co-infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin.	J Med Virol	89(1)	99-105	2017
Ikeda H, Nozaki A, Shimizu H, Inoue K, Hattori N, Hiraishi T, Ishii T, Yamada N, Kato T, Shigefuku R, Matsunaga K, <u>Matsumoto N</u> , Iwabuchi S, Suzuki M, Itoh F, Watanabe T, Okuse C, Tanaka K.	Real-world effectiveness of sofosbuvir plus ribavirin in Japanese patients with genotype 2 HCV infection: A kanagawa prospective, multicenter study.	Acta Hepatologica Japonica	57(10)	561-564	2016

Sato A, Ishii T, Sano F, Yamada T, Takahashi H, <u>Matsumoto N.</u>	Severe de novo Hepatitis B Recovered from Late-Onset Liver Insufficiency with Prolonged Ascites and Hypoalbuminemia due to Hepatitis B Virus Genotype B 1 with Precore Mutation.	Case Rep Gastroenterol.	10(3)	553-559	2016
Shigefuku R, Takahashi H, Nakano H, Watanabe T, Matsunaga K, <u>Matsumoto N.</u> , Kato M, Morita R, Michikawa Y, Tamura T, Hiraishi T, Hattori N, Noguchi Y, Nakahara K, Ikeda H, Ishii T, Okuse C, Sase S, Itoh F, Suzuki M.	Correlations of hepatic hemodynamics, liver function, and fibrosis markers in nonalcoholic fatty liver disease: Comparison with chronic hepatitis related to hepatitis C virus.	Int J Mol Sci.	17(9)	e1545	2016
Sato A, Ishii T, Adachi K, Takahashi H, Sano F, <u>Matsumoto N.</u>	Delayed Viral Clearance after 6-Week Treatment with Peginterferon Plus Ribavirin in a Patient with Chronic Hepatitis C Virus Genotype 1b.	Case Rep Gastroenterol.	10(2)	417-422	2016
Sato A, Ishii T, Adachi K, Kumon D, Tamura T, Noguchi Y, <u>Matsumoto N.</u> , Okuse C.	Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy.	Clin J Gastroenterol	9(2)	89-92	2016
Younossi ZM, Tanaka A, <u>Eguchi Y</u> , Lim Y S, Yu ML, Kawada N, Dan YY, Brooks-Rooney C, Negro F, Mondelli MU.	The impact of hepatitis C virus outside the liver: Evidence from Asia.	Liver Int.		2016 Oct 17. [Epub ahead of print] Review.	2016
Oeda S, Iwane S, Takasaki M, Furukawa NE, Otsuka T, <u>Eguchi Y</u> , Anzai K.	Optimal Follow-up of Patients with Viral Hepatitis Improves the Detection of Early-stage Hepatocellular Carcinoma and the Prognosis of Survival.	Intern Med.	55(19)	2749-2758.	2016

Ide T, Eguchi Y, Harada M, Ishii K, Morita M, Morita Y, Sugiyama G, Fukushima H, Yano Y, Noguchi K, Nakamura H, Hisatomi J, Kumemura H, Shirachi M, Iwane S, Okada M, Honma Y, Arinaga-Hino T, Miyajima I, Ogata K, Kuwahara R, Amano K, Kawaguchi T, Kuromatsu R, Torimura T;	DAAs Multicenter Study Group.. Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1.	PLoS One.	29;11(9)	e0163884.	2016
Eguchi Y, Furukawa N, Furukawa T, Egashira Y, Hotokezaka H, Oeda S, Iwane S, Anzai K.	"Weariness" and "unpleasantness" reduces adherence to branched-chain amino acid granules among Japanese patients with liver cirrhosis: results of a single-center cross-sectional survey.	Hepatol Re	[Epub ahead of print]		2016
E Furukawa N, Yamashita S, Maeyama K, Oeda S, Iwane S, Hirai K, Ozaki I, Eguchi Y.	Clinical course of hepatitis B surface antigen positive subjects following screening: A retrospective observational study from April 2008 to January 2013.	Hepatol Re	46(7)	678-85.	2016
Kondo Y	Hepatitis C infected patients need vitamin D3 supplementation in the era of direct acting antivirals treatment	World Journal of Gastroenterology	Feb 28;23(8)	1325-1327	2017
Chen CL, Huang J, Wang CH, Zhou L, Kondo Y, Schechter J, Su L, Lai MM, Wakita T, Cosset FL, Jung JU, Machida K	Hepatitis C virus has a genetically determined lymphotropism through receptor B7.2	Nature Communications	Jan 9	8:13882.	2017
末次 淳	C型肝炎ウイルスの最新治療	岐阜県医師会医学雑誌	第 29巻	45-48	2016